

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgil Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenber Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordol Laura A. Yogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tang Christopher J. Walsh W. Blake Coblentz James J. Pohl John T. Haran Mark W. Rygiel

Michael R. Malek* Carla Ji-Eun Kim Doyle A. Siever* Ulrike Winkler Bryan L. Skelton* Paul A. Calvo Robert A. Schwartzman C. Matthew Rozier Alexandra K. Pechhold

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

June 20, 2007

WRITER'S DIRECT NUMBER: (202) 772-8851 INTERNET ADDRESS: RSCHWART@SKGF.COM

Mail Stop: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Appl. No. 10/589,435; 35 U.S.C. § 371(c) Date: August 15, 2006

For: Prevention of Arterial Restenosis with Active Vitamin D Compounds

Inventors: Whitehouse *et al.*

Our Ref: 2035.0240001/RWE/RAS

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. One (1) page of Form PTO/SB/08A citing twelve (12) documents; and
- 3. A copy of three (3) of the cited documents (FP4-FP6).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Attorney for Applicants Registration No. 50,211

RAS/las Enclosures 689382_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Confirmation No.: 9874

Whitehouse *et al.* Art Unit: 1614

Appl. No.: 10/589,435 Examiner: To Be Assigned

§ 371 Date: August 15, 2006 Atty. Docket: 2035.0240001/RWE/RAS

For: **Prevention of Arterial Restenosis** with Active Vitamin D Compounds

First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08A, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on August 15, 2006 in connection with the above-captioned application.

Copies of documents **FP4** to **FP6** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **US35** to **US42**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Whitehouse *et al.* Appl. No. 10/589,435

- 2 -

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Attorney for Applicants Registration No. 50,211

Date:

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

6/20/2007

685196v1

Equivalent of Form PTO/SB/08A (04-07) Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur

Substitute for form 1449/PTO				Complete if Known		
EIDET	SHE	DI EA	/IENTAL	Application Number	10/589,435	
				§ 371 Date	August 15, 2006	
			DISCLOSURE	First Named Inventor	Whitehouse, Martha J.	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Art Unit	1614	
				Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number	2035.0240001/RWE/RAS	

			U.S. PATENT DO	OCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (If Known)}			
	US35	2006/0172014 A1	08/03/2006	Curd et al.	
	US36	2006/0178351 A1	08/10/2006	Curd et al.	
	US37	2006/0177374 A1	08/10/2006	Curd et al.	
	US38	2006/0189586 A1	08/24/2006	Cleland	
	US39	2007/0003614 A1	01/04/2007	Chen et al.	
	US40	2007/0027120 A1	02/01/2007	Whitehouse et al.	
	US41	2007/0037779 A1	02/15/2007	Curd et al.	
·	US42	2007/0004688 a1	01/04/2007	Laidlaw et al.	

		1			<u> </u>
					

		Fo	REIGN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
	FP4	WO 2005/117542 A2	12/15/2005	Novacea, Inc. and Curd, J.G.		
	FP5	WO 2006/116204 A1	11/02/2006	Novacea, Inc. and Curd, J.G.		
-	FP6	WO 2007/038428 A2	04/05/2007	Novacea, Inc. and Curd, J.G.		
685174v						

Examiner Date Signature Considered

English language I ransiation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.